Effect of bimatoprost sustained-release intracameral implant on intraocular pressure and medication burden in patients with prior glaucoma surgery.
Bimatoprost SR
Chirurgie
Glaucoma
Glaucome
Implant intracaméral
Intracameral implant
Intraocular pressure
Pression intraocculaire
Surgery
Journal
Journal francais d'ophtalmologie
ISSN: 1773-0597
Titre abrégé: J Fr Ophtalmol
Pays: France
ID NLM: 7804128
Informations de publication
Date de publication:
03 Nov 2023
03 Nov 2023
Historique:
received:
15
05
2023
revised:
01
07
2023
accepted:
03
07
2023
medline:
6
11
2023
pubmed:
6
11
2023
entrez:
5
11
2023
Statut:
aheadofprint
Résumé
The present retrospective study evaluated intraocular pressure (IOP) and medication burden after bimatoprost sustained-release (bimatoprost SR, Durysta, Allergan) implantation in patients with glaucoma. A secondary objective was to examine an effect of bimatoprost SR in a subset of patients with prior minimally invasive and incisional glaucoma surgery. A retrospective chart review of 122 eyes that received bimatoprost SR by 6 glaucoma specialists at Wills Eye Hospital between March 2020 and September 2021 was performed. One hundred and eighteen eyes from 84 patients had a reduction in IOP (18.5±5.7mmHg vs. 16.0±5.4mmHg, P<0.01) and required fewer glaucoma medications (2.1±1.4 vs. 1.2±1.2, P<0.01) after bimatoprost SR implantation. In 41 eyes from 31 patients who previously underwent glaucoma surgery (including iStent, goniotomy, trabeculectomy, Xen Gel Stent, or tube shunt surgery), medication burden was decreased after bimatoprost SR implantation (1.9±1.3 vs. 1.0±1.0, P<0.001). These data suggest that bimatoprost SR is an efficacious treatment modality for glaucoma, even in post-surgical patients.
Identifiants
pubmed: 37926661
pii: S0181-5512(23)00477-1
doi: 10.1016/j.jfo.2023.07.016
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.